Given his FLT-3 status, midostaurin, a kinase inhibitor approved by the FDA to treat FLT-3 mutation-positive AML, was added on day 10 of the second induction attempt, administered for the next 14 days, and repeated on days 8–21 of each cycle. Here, FLT3 is linked to acute myeloid leukemia.